SYKT Alleviates Doxorubicin-Induced Cardiotoxicity via Modulating ROS-Mediated p53 and MAPK Signal Pathways

<div>SYKT inhibits DOX-induced p53 activation. (A) DOX induces p53 expression in a time-dependent manner. Cardiomyocytes were treated with DOX for the indicated periods, and the p53 levels were analyzed by immunoblotting. <i>β</i>-Actin served as a loading control. (B) Effects of DOX (1 <i>μ</i>M for 3 h), SYKT (30 mg/ml), and PFT-<i>α</i> (40 <i>μ</i>M) on p53 expression. <sup>a</sup><i>p</i> &lt; 0.05 versus control; <sup>b</sup><i>p</i> &lt; 0.05 versus DOX;<i> n</i> = 6.</div>

Evidence-Based Complementary and Alternative Medicine

fig2

Figure 2

Figure 2: SYKT Alleviates Doxorubicin-Induced Cardiotoxicity via Modulating ROS-Mediated p53 and MAPK Signal Pathways 